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At this time of the COVID-19 pandemic, potentially effective treatments are currently
under urgent investigation. Benefits of chloroquine and hydroxychloroquine for the
treatment of COVID-19 infection have been proposed and clinical trials are underway.
Chloroquine and hydroxychloroquine, typically used for the treatment of malaria and
autoimmune diseases, have been considered for off-label use in several countries. In
the literature, there are reports of ototoxic effects of the drugs causing damage to
the inner ear structures, which then result in hearing loss, tinnitus, and/or imbalance.
This mini-review represents a summary of the findings from a systematic search
regarding ototoxicity of chloroquine and hydroxychloroquine in the published literature.
The characteristics of sensorineural hearing loss and/or tinnitus after chloroquine or
hydroxychloroquine treatment can be temporary but reports of persistent auditory and
vestibular dysfunction exist. These are not frequent, but the impact can be substantial.
Additionally, abnormal cochleovestibular development in the newborn was also reported
after chloroquine treatment in pregnant women. The suggested dose of chloroquine for
COVID-19 infection is considerably higher than the usual dosage for malaria treatment;
therefore, it is plausible that the ototoxic effects will be greater. There are potential
implications from this review for survivors of COVID-19 treated with chloroquine or
hydroxychloroquine. Patient reports of hearing loss, tinnitus, or imbalance should be
noted. Those with troublesome hearing loss, tinnitus and/or imbalance are encouraged
to be referred for hearing evaluation and interventions once they are stable. Clinical
trials of chloroquine or hydroxychloroquine should also consider including audiological
monitoring in the protocol.
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INTRODUCTION
At this time of the COVID-19 global pandemic, potentially effective treatments are currently
under urgent investigation. Currently, there is no evidence from randomized clinical trials
that any specific therapy improves outcomes in patients with COVID-19 (1). Chloroquine and
hydroxychloroquine are considered to be promising repurposed drugs against COVID-19, based on
Prayuenyong et al. Chloroquine and Hydroxychloroquine Ototoxicity
pathophysiological considerations and in vitro results (2, 3).
These drugs have received particular attention as they are widely
available and inexpensive. Chloroquine and hydroxychloroquine,
quinine-related compounds, have been used for the treatment
of malaria and chronic inflammatory diseases such as systemic
lupus erythematosus and rheumatoid arthritis. The anti-viral
and anti-inflammatory properties may account for the efficacy
in treating patients with COVID-19 infection (4). There
have been reports that patients who received chloroquine
or hydroxychloroquine had faster virological clearance (5,
6), however there are some limitations of the studies such
as small sample size and questionable methodology. There
is no high-quality evidence of potential benefit of these
drugs at the moment. Presently, there are over 80 registered
ongoing trials worldwide examining the role of chloroquine and
hydroxychloroquine in COVID-19 treatment (7).
Clinical practice guidelines have considered chloroquine and
hydroxychloroquine for off-label and compassionate therapies
against moderate to severe cases of COVID-19 in several
countries including China, Korea, USA, France, Italy, and
Belgium (8). There is currently also a massive global demand for
chloroquine and hydroxychloroquine as people around the world
are self-medicating after health professionals and politicians
have endorsed the drugs. Chloroquine and hydroxychloroquine
are also freely available in the UK and other countries
without prescription.
Some potential side effects of chloroquine and
hydroxychloroquine are cardiac arrhythmias, retinopathy,
and muscle weakness (4). The clinical and research literature
also contains reports of ototoxic effects after chloroquine and
hydroxychloroquine treatment. Ototoxicity refers to drug-related
injury causing damage to the inner ear structures, which then
result in hearing loss and/or tinnitus (the subjective perception
of sound such as ringing, hissing, or buzzing, without an external
source), and/or imbalance (9). Permanent hearing loss can
adversely affect cognitive health (10) and mental well-being
(11). Troublesome tinnitus is associated with insomnia, poor
concentration, anxiety and depression (12). The mechanisms of
chloroquine associated hearing loss include cochlear outer hair
cell dysfunction, and inhibition of post synaptic sodium channel
function in cochlear spiral ganglion cells (13). Additionally,
some alterations in central auditory function, which may trigger
tinnitus, have been observed after quinine administration (13).
This mini-review represents a summary of the findings
from a literature search regarding ototoxicity of the drugs in
the published literature as well as the discussion of potential
implications for survivors of COVID-19 so treated.
METHOD
A systematic literature search on Medline and EMBASE
platforms was undertaken on 26th March 2020, updated on
23rd April 2020. The search strategy combined MeSH terms and
keywords of chloroquine or hydroxychloroquine, ototoxicity,
hearing loss, hearing, tinnitus. English language publications
containing relevant data to this review were included. Data
extraction items included year, study design, sample size, and
audiological outcomes. Data were collated in the table and
then summarized by narrative synthesis. Recommendations from
audiological professional perspectives were then made.
RESULTS
Chloroquine Ototoxicity
Eleven publications, reporting topics associated with ototoxic
effects of chloroquine, were identified and are summarized in
Table 1. The year of publication ranged from 1954 to 2015. There
were 7 case reports, 2 observational studies, 1 case control study,
and 1 review article. The sample size of the study participants
varied from 1 to 74.
Ten patients (8 adults and 2 children) in 6 publications
had either abnormal audiogram or reported hearing loss
after chloroquine treatment. Three out of ten cases had
temporary sensorineural hearing loss after chloroquine treatment
that improved after cessation of the medication (14, 19). A
prospective observational study in 2015 concluded that ototoxic
effects of chloroquine at regular doses formalaria treatment (1.2 g
daily for 3 days) were fully reversible (14). Sensorineural hearing
loss after chloroquine in a 6-year old girl was partially reversible
after prednisolone administration (19). However, permanent
severe sensorineural hearing loss has also been reported in 2 cases
(17, 20). Additionally, reversible chloroquine-induced cochlear
injury was detectable by brainstem audiometry in 13 out of
70 patients despite normal pure tone audiogram results (18).
Tinnitus has also been reported concurrently with persistent
hearing loss in 1 case (20). Imbalance was reported in 3 cases
(14, 19, 20).
While there was no difference in hearing thresholds between
children who were and were not exposed to chloroquine during
gestation (16), there were 3 case reports of intrauterine effects
of chloroquine associated with abnormal cochleovestibular
development in newborns (21, 22).
Hydroxychloroquine Ototoxicity
Six case reports, describing ototoxic effects associated
with hydroxychloroquine, were identified and are
displayed in Table 2. Publication year ranged from 1998
to 2018. Sensorineural hearing loss was identified after
hydroxychloroquine treatment in five adults and two children.
The sensorineural hearing loss was found to be either reversible
(25, 28) or irreversible (24, 29). The onset of hearing loss after
hydroxychloroquine treatment varied from 1 month (25) to
several years (29). Tinnitus was also reported concomitantly with
hearing loss in 2 cases (24, 28).
Discussion
The manifestation of sensorineural hearing loss and/or tinnitus
and/or imbalance after chloroquine and hydroxychloroquine
can be either temporary or permanent. Most of the studies
on this topic were case series or case reports with only a few
observational studies. Information from a definitive large
study with good methodology is still lacking. Ototoxicity
after chloroquine use tends to be more sudden, while
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TABLE 1 | Chloroquine ototoxicity.
Title References Study type Sample size Dosage Results
Assessment of short term
chloroquine-induced
ototoxicity in malaria patients
(14)
Subramaniam
and Vaswani (14)
Prospective
observational
study
30 (Aged
14-58
years old)
1200mg loading
load then
600mg oral
every 12 hours
for 2 days
- 2 subjects showed a change in hearing thresholds on high frequency audiometry
(8-12 kHz). Pure tone audiometry showed bilateral mild sensorineural hearing
loss at 12 kHz in 1 subject, and bilateral mild to moderate sensorineural hearing
loss at 8 kHz in another. The otoacoustic emission (OAE) and auditory brainstem
response (ABR) findings were also abnormal in these 2 subjects. A 1 month
follow-up Pure Tone Audiogram was normal.
- 1 subject showed vestibular side effects in the form of ‘giddiness’ and
nystagmus which spontaneously resolved on completion of therapy.
Chloroquine ototoxicity (15) Bortoli and
Santiago M (15)
Review – – – Some reports have described sensorineural hearing loss, tinnitus, sense of
imbalance after prolonged high dose of chloroquine.
- The reversibility of chloroquine ototoxicity has been debatable.
Chloroquine gestational use in
systemic lupus
erythematosus: assessing the
risk of child ototoxicity by pure
tone audiometry (16)
Borba et al. (16) Case-control
study
19 (Mean age
of mothers
was 27
years old)
250mg daily - There was no difference in hearing thresholds by pure tone audiometry of
children between chloroquine exposure and non-exposure groups during the
gestation. The mean hearing thresholds (Pure Tone Audiometry) at low
frequencies of exposure and non-exposure groups were similar (11.4 ± 4.5 vs.
11.9 ± 3.0 dB; p = 0.66). The mean hearing threshold at high frequencies of
exposure and non-exposure groups were not significantly different (8.5 ± 5.0
vs. 7.4 ± 3.6 dB; p = 0.55).
Chloroquine ototoxicity: an
idiosyncratic phenomenon
(17)
Hadi et al. (17) Case report of a
2.5-year-old boy
1 No information - Abnormal gait a few hours after single chloroquine intramuscular injection.
Severe hearing loss on the 2nd day. 10 days later, he was treated with steroid
and plasma expander. He still had permanent severe hearing loss at 3-5 years
follow up. No testing technique information given.
Alterations of auditory evoked
potentials during the course of
chloroquine treatment (18)
Bernard (18) Observational
study
74 No information - There was no hearing change by pure tone audiogram.
- There were abnormal results of brainstem audiometry (Auditory Brainstem
Audiometry) in 13 patients which resolved after chloroquine discontinuation.
Chloroquine ototoxicity—a
reversible phenomenon? (19)
Mukherjee (19) Case report of a
6-year-old girl
1 250mg
intramuscular
injection daily for
7 days
- She complained of hearing loss, and had abnormal gait after chloroquine
injection for malaria. Pure Tone Audiometry indicated severe unilateral
sensorineural hearing loss, which was worse at mid frequencies (mean hearing
threshold at mid frequencies = 80 dB)
- Patient hearing improved after prednisolone administration, and Pure Tone
Audiometry indicated the mean hearing threshold at mid frequencies was 35
dB bilaterally.
Ototoxicity of chloroquine
phosphate: a case report (20)
Dwivedi and
Mehra (20)
Case report of a
52-year-old man
1 1,000mg
loading load
- The patient had bilateral permanent deafness, severe vomiting, vertigo,
blurring of vision and tinnitus at 1.5 hour after taking a single dose of 1g of
chloroquine. Pure tone audiometry indicated hearing thresholds of more than
90 dB in both ears.
Sudden deafness and
chloroquine injection:
personal communication
Obiako (personal
communication)
Case report 4 No information - There were 4 cases of sensorineural deafness following chloroquine
phosphate injections. No testing technique information given.
Ototoxicity of chloroquine (21) Matz and
Naunton (21)
Case report 1 No information - There was a complete absence of inner and outer hair cells throughout the
length of the cochlea in a deaf child whose mother took chloroquine during
pregnancy. No testing technique information given.
The ototoxicity of chloroquine
phosphate (22)
Hart and
Naunton (22)
Case report 2 No information - There were 2 cases of severe bilateral cochleovestibular paresis whose
mothers were treated with chloroquine during her pregnancy.No testing
technique information given.
Chloroquine in lupus
erythematosus
Dewar and
Mann (23)
Case report 1 No information - The patient had irreversible sensorineural deafness, after being treated with
chloroquine for 7 months. No testing technique information given.
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TABLE 2 | Hydroxychloroquine ototoxicity.
Title References Study type Sample size Dosage Results
Hydroxychloroquine
ototoxicity in a patient with
systemic lupus erythematosus
(24)
Fernandes et al.
(24)
Case report of a
51-year-old
woman
1 400mg daily - Patient complained of tinnitus and bilateral hearing loss, 3 years after
sustained hydroxychloroquine use. Pure Tone audiometry indicated moderate
sensorineural hearing loss in the left ear, and mild to moderate in the right ear.
Her hearing loss and tinnitus persisted after the discontinuation of medication.
A case report of hearing loss
post use of
hydroxychloroquine in a
HIV-infected patient (25)
Khalili et al. (25) Case report of a
57-year old man
1 400mg daily - Bilateral slowly progressive reversible sensorineural hearing loss after 1 month
of hydroxychloroquine. Pure Tone Audiometry indicated moderate to severe
sensorineural hearing loss bilaterally. Two months after the discontinuation of
hydroxychloroquine, audiometric findings improved, showing mild to moderate
hearing loss in both ears.
Hydroxychloroquine-induced
ototoxicity in a child with
systemic lupus erythematosus
(26)
Lim and Tang
(26)
Case report of a
11-year old girl
1 100mg daily (3
mg/kg/d)
- Patient complained of reduced hearing after 2 months of hydroxychloroquine
use. Pure Tone Audiometry indicated bilateral sensorineural hearing loss,
predominantly affecting the low-frequency range.
Hydroxychloroquine
ototoxicity in a child with
idiopathic pulmonary
haemosiderosis (27)
Coutinho and
Duarte (27)
Case report of a
7-year-old girl
1 200mg daily - Patient had unilateral slowly progressive hearing loss after 2 years of
hydroxychloroquine use. Pure Tone Audiometry indicated moderate to severe
sensorineural hearing loss (mean hearing threshold 65 dB). The auditory
brainstem response (ABR) test showed absence of response at 90 dB in the
right ear.
Hydroxychloroquine
ototoxicity in a patient with
rheumatoid arthritis (28)
Seckin et al. (28) Case report of a
34-year-old
woman
1 400mg daily - Patient complained of hearing loss and tinnitus after 5 months of
hydroxychloroquine use. Pure Tone Audiometry indicated bilateral mild
sensorineural hearing loss. After discontinuation of hydroxychloroquine, patient
symptoms improved and the follow-up audiogram was normal.
Otoxicity due to
hydroxychloroquine: report of
two cases (29)
Johansen and
Gran (29)
Case report of a
44-year-old
woman and a
44-year-old man
2 No information - Patients had irreversible sensorineural hearing loss after several years of
hydroxychloroquine use. No testing technique information given.
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hydroxychloroquine is more likely to cause ototoxicity
after prolonged use. This could be due to different drug
efficacy and equivalent dosage. Furthermore, hearing loss
in these patients could be associated with other possible
causes rather than chloroquine and hydroxychloroquine
including autoimmune disease e.g., systemic lupus
erythematosus (30), sudden sensorineural hearing loss
or presbycusis.
The suggested dose of chloroquine for patients diagnosed
with COVID-19 infection (1 g daily for 10 days) is substantially
higher compared with the usual dosage of chloroquine for
malaria treatment (1 g daily for 3 days) (5). There is no
information regarding the ototoxic effect of chloroquine at
this higher dose. Patients with chronic inflammatory diseases
were treated with a usual dose of hydroxychloroquine 400mg
daily for long durations (months or years). A suggested dose
of hydroxychloroquine for COVID-19 infection is an initial
loading dose of 800mg followed by 400mg daily for 4 days
based on the in vitro model (2), and 600mg daily for 10
days from a French study (6). In general, the recommended
dosage of hydroxychloroquine in COVID-19 patients is slightly
higher but in a shorter duration compared to that in
autoimmune disease. The ototoxic effects of these regimens
are unknown.
Due to the potentially substantial number of the world’s
population who may take chloroquine or hydroxychloroquine,
there is the prospect of a significant number of people
being affected with ototoxic side effects. It is therefore vital
to build awareness about the presentation and impact of
the symptoms of drug-induced ototoxicity. Patient reports of
hearing loss, tinnitus, or imbalance should be noted. Those
with troublesome hearing loss or tinnitus are encouraged to
be referred for hearing evaluation, including extended high
frequencies audiometry at 8–16 kHz where possible, once they
are stable. Available options of audiological interventions for
those with bothersome hearing impairment or tinnitus are
counseling, hearing aids, and tinnitus therapy. The possibility
of exacerbation of pre-existing hearing loss and/or tinnitus
should be considered. Synergistic adverse auditory effects when
other ototoxic medication is administered with chloroquine
or hydroxychloroquine, such as aminoglycoside antibiotics and
azithromycin, is a further risk (9). Severe cases of COVID-19 can
also progress to respiratory distress and hypoxia (31). Hypoxia
is known to have deleterious effects on the stria vascularis of
the cochlea organ including alterations to cochlear potentials and
histologic changes (32). Therefore, it is certainly possible that the
combined effects of hypoxia and administration of chloroquine
or hydroxychloroquine on hearing could be worse than either
one alone. Clinical trials of chloroquine or hydroxychloroquine
should also consider including audiological monitoring in the
protocol. Ideally, a hearing test should be conducted both before
and after drug administration to examine drug-induced hearing
change. Common methods for audiological evaluation include
pure tone audiometry, otoacoustic emission (OAE), and tinnitus
questionnaire. However, conventional methods and setting of
hearing evaluation is impractical based on the infectious nature
of COVID-19 and the urgency of drug administration. Self-
monitoring by validated smartphone-based apps for hearing
assessments in addition to self-report of symptoms is an approach
of interest in this situation.
Although chloroquine and hydroxychloroquine are
generally considered safe in pregnant women, the use of
chloroquine during pregnancy in the first trimester should be
contemplated with particular caution since there are reports
of abnormal cochleovestibular development in newborns.
Hydroxychloroquine has a safer clinical profile in pregnancy,
thus is a more suitable option than chloroquine (33).
Conclusion
Recent publications have brought attention to the possible
benefit of chloroquine and hydroxychloroquine in COVID-
19 treatment. It is important to build awareness about the
possibility of ototoxicity in survivors of COVID-19 treated
with these drugs. Patient reports of hearing loss, tinnitus, or
imbalance should be noted. Those with troublesome hearing
loss or tinnitus are encouraged to be referred for hearing
evaluation and interventions once they are stable. Clinical trials
of chloroquine or hydroxychloroquine should also consider
including audiological monitoring in the protocol.
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